EKTABS Stock Overview A medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Elekta AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Elekta Historical stock prices Current Share Price SEK 69.88 52 Week High SEK 87.93 52 Week Low SEK 63.78 Beta 1.12 1 Month Change 0% 3 Month Change n/a 1 Year Change -13.97% 3 Year Change -35.60% 5 Year Change -38.68% Change since IPO -79.27%
Recent News & Updates Elekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025
Caroline Leksell Cooke Steps Down from Elekta AB's Board of Directors Nov 01
Elekta AB Submits Elekta Evo to U.S. FDA for Premarket Approval Sep 27 Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, Respectively Sep 06
Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025 Jul 06
Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025 Jun 06 See more updates Elekta AB (publ) to Report Q2, 2026 Results on Nov 26, 2025
Caroline Leksell Cooke Steps Down from Elekta AB's Board of Directors Nov 01
Elekta AB Submits Elekta Evo to U.S. FDA for Premarket Approval Sep 27 Elekta AB (Publ) Approves Dividend, Payable on September 12, 2024, and on March 12, 2025, Respectively Sep 06
Elekta AB (publ) to Report Q4, 2025 Results on May 28, 2025 Jul 06
Elekta AB (publ) to Report Q3, 2025 Results on Feb 21, 2025 Jun 06
Elekta AB (publ) Announces Resignation of Kelly Londy, Member of the Board Mar 02
Elekta AB (publ) to Report Q2, 2025 Results on Nov 27, 2024 Feb 29 Elekta AB (publ) to Report Fiscal Year 2024 Final Results on Jul 05, 2024
Elekta AB (publ) Announces Composition of Nomination Committee Nov 01
Elekta AB (publ) (OM:EKTA B) agreed to acquire Xoft, Inc. from iCAD, Inc. (NasdaqCM:ICAD). Oct 24
Elekta AB (publ), Annual General Meeting, Sep 05, 2024 Oct 13
Founder & Chairman recently sold kr60m worth of stock Sep 24
First quarter 2024 earnings released: EPS: kr0.62 (vs kr0.16 in 1Q 2023) Aug 26 Elekta AB (Publ) Approves Dividend, Payable on 31 August, 2023 and 1 March, 2024, Respectively
Upcoming dividend of kr1.20 per share at 3.1% yield Aug 18
Insufficient new directors Aug 16
Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022) Jul 10
President & CEO recently bought kr501k worth of stock Jul 05
Johan Malmquist Declines Re-Election as Director of Elekta AB (Publ) Jun 30
Insufficient new directors Jun 20
Full year 2023 earnings released: EPS: kr2.47 (vs kr3.02 in FY 2022) May 27 Elekta AB (publ) to Report Q3, 2024 Results on Feb 09, 2024 Elekta AB (publ) Provides Earnings Guidance for the Fiscal Year from 2022-2023 to 2024-2025
Elekta AB (Publ) Announces the Launch of the First Phase of Elekta ONE May 13
Insufficient new directors Mar 31
Third quarter 2023 earnings released Feb 26
Insufficient new directors Feb 23
Upcoming dividend of kr1.20 per share at 3.2% yield Feb 17
Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter. Feb 14
Elekta AB (publ) (OM:EKTA B) entered into an agreement to acquire business assets of Premier Business Inter. Feb 13
Insufficient new directors Feb 09
Insufficient new directors Jan 26
Independent Director recently bought kr63k worth of stock Jan 06
Insufficient new directors Jan 06
Insufficient new directors Dec 21
First Ever Patient Treated for Pancreatic Cancer with New Advanced Radiotherapy Motion Management Using Elekta Unity MR-Linac Dec 13
Second quarter 2023 earnings released Nov 25
Elekta AB (publ), Annual General Meeting, Aug 24, 2023 Nov 24
Swedish and Jordanian Royalty Inaugurate Elekta AB (publ) Radiation Therapy Devices for Cancer and Brain Disease Nov 18
Insufficient new directors Nov 16
Elekta AB (publ) Announces Elekta Esprit Receives FDA 510(k) Clearance Oct 28
Elekta Unity Demonstrates Promising Quality of Life Outcomes for Pancreas and Prostate Cancers At Astro Annual Meeting Oct 26
Elekta AB (publ)(OM:EKTA B) dropped from FTSE All-World Index (USD) Sep 19 Elekta AB (publ) Elects Kelly Londy as a Director
First quarter 2023 earnings released: EPS: kr0.16 (vs kr0.33 in 1Q 2022) Aug 26
Upcoming dividend of kr1.20 per share Aug 19
Insufficient new directors Aug 12
Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021) Jul 13 Elekta AB (publ) to Report Fiscal Year 2023 Results on May 25, 2023
Chief Product Officer recently bought kr420k worth of stock Jun 23
Full year 2022 earnings released: EPS: kr3.02 (vs kr3.28 in FY 2021) May 26
Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021/22 May 26
Elekta Launches New Radiosurgery System: Elekta Esprit May 08
Insufficient new directors Apr 29 Elekta AB (publ) to Report Fiscal Year 2022 Final Results on Jul 08, 2022
Insider recently bought kr518k worth of stock Feb 26
Third quarter 2022 earnings: Revenues in line with analyst expectations Feb 25
Elekta AB (publ), Annual General Meeting, Aug 25, 2022 Feb 24
Upcoming dividend of kr1.10 per share Feb 18
President of Brachy Solutions recently bought kr305k worth of stock Dec 15
Independent Director recently bought kr1.1m worth of stock Nov 28
Second quarter 2022 earnings: Revenues exceed analyst expectations Nov 27
Insufficient new directors Oct 28
Founder & Chairman recently bought kr49m worth of stock Oct 13
Elekta AB (publ) (OM:EKTA B) acquired Özyürek Mümessillik ve Dis Ticaret A.S. Sep 03
First quarter 2022 earnings released: EPS kr0.33 (vs kr0.56 in 1Q 2021) Aug 26
Upcoming dividend of kr1.10 per share Aug 19
Insufficient new directors Jul 29
Full year 2021 earnings released: EPS kr3.28 (vs kr2.84 in FY 2020) Jul 10
President & CEO recently bought kr1.0m worth of stock Jul 02
Elekta AB (Publ)'s Elekta Harmony Radiation Therapy System Receives U.S. FDA 510(K) Clearance Jun 17
CFO & Group Treasurer recently bought kr492k worth of stock Jun 13
Full year 2021 earnings released: EPS kr3.28 (vs kr2.84 in FY 2020) May 30
Elekta AB (Publ) Proposes Dividend for the Fiscal Year 2021 May 28
Elekta AB (Publ) Approves Extra Dividend, Payable on 23 April 2021 Apr 18
Elekta AB (publ) Proposes Extra Dividend, Payable on 23 April 2021 Mar 21
Elekta and IBA Strengthen Partnership to Help Cancer Centers Integrate Proton Therapy Mar 05 Elekta Not Provides Earnings Guidance for the Year of 2021
First Cancer Centers Begin Using Initial Release of Elekta's MOSAIQ 3 Series Feb 25
Elekta AB (publ) (OM:EKTA B) signed an agreement to acquire Oncology division from Horizon for Medical Appliances. Feb 23
Elekta's ProKnow to Help Standardize Radiotherapy for Veterans Feb 11
An unknown buyer acquired 7.3% stake in ViewRay, Inc. (NasdaqGM:VRAY) from Elekta AB (publ) (OM:EKTA B) for $53.5 million. Jan 22
New 90-day high: kr116 Jan 19
Second quarter 2021 earnings released: EPS kr0.98 Dec 01
Independent Director recently bought kr214k worth of stock Dec 01 Shareholder Returns EKTABS GB Medical Equipment GB Market 7D 0% 0.09% 0.4% 1Y -14.0% -10.3% 4.8%
See full shareholder returns
Return vs Market: EKTABS underperformed the UK Market which returned 4.8% over the past year.
Price Volatility Is EKTABS's price volatile compared to industry and market? EKTABS volatility EKTABS Average Weekly Movement n/a Medical Equipment Industry Average Movement 6.5% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: EKTABS's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine EKTABS's volatility change over the past year.
About the Company Founded Employees CEO Website 1972 4,580 Gustaf Salford elekta.com
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software.
Show more Elekta AB (publ) Fundamentals Summary How do Elekta's earnings and revenue compare to its market cap? EKTABS fundamental statistics Market cap SEK 23.48b Earnings (TTM ) SEK 1.00b Revenue (TTM ) SEK 17.72b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EKTABS income statement (TTM ) Revenue SEK 17.72b Cost of Revenue SEK 11.25b Gross Profit SEK 6.48b Other Expenses SEK 5.48b Earnings SEK 1.00b
Last Reported Earnings
Oct 31, 2024
Next Earnings Date
Feb 21, 2025
Earnings per share (EPS) 2.62 Gross Margin 36.55% Net Profit Margin 5.65% Debt/Equity Ratio 76.9%
How did EKTABS perform over the long term?
See historical performance and comparison Dividends
2.0% Current Dividend Yield When do you need to buy EKTABS by to receive an upcoming dividend? Elekta dividend dates Ex Dividend Date Mar 06 2025 Dividend Pay Date Mar 12 2025 Days until Ex dividend 55 days Days until Dividend pay date 61 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/09 13:43 End of Day Share Price 2024/10/22 00:00 Earnings 2024/10/31 Annual Earnings 2024/04/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Elekta AB (publ) is covered by 39 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Sumit Sayal AlphaValue Alexander Kleban Barclays Hassan Al-Wakeel Barclays
Show 36 more analysts 
